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A novel series of platinum (II) complexes was synthesized and the complexes were evaluated for their 
in vitro cytotoxicity against four human cancer cells lines. Five platinum complexes showed activity 
against at least one tumor cell line. Complexes 3 and 6 were promising, being active, at micromolar 
concentrations, against all the assayed tumor cell lines. Compound 3 was selected for further studies in 
mice with Ehrlich solid tumors and it was able to reduce the rate of tumor growth significantly during 
the first seven days. However, at the end of the experiments, there was no significant difference between 
the group of animals treated with 3 and the control group. The low solubility of the compound in the 
assay conditions can explain, at least in part, these results.
Uniterms:. /Cytotoxic activity. Platinum complexes/ Ehrlich solid tumor activity.
INTRODUCTION
Considered as a public health problem, cancer 
affects people of all ages, races, gender and nationality. It 
is the second major cause of death by disease worldwide. 
According to World Health Organization, 8.2 million 
people worldwide died from cancer in 2012 and this 
number is expected to rise to 13.1 million deaths in 2030 
(WHO, 2015). 
Cisplatin [cis-diamminedichloroplatinum (II)] is 
an antitumor drug used to treat different types of cancer, 
including testicular cancer, germ cell cancer, lymphoma, 
and ovarian cancer. It is one of the most widely used 
and effective antineoplastic agents (Gómez-Ruiz et al., 
2012). However, its clinical usefulness is often limited by 
severe side effects, such as nephrotoxicity, ototoxicity and 
neurotoxicity, and development of resistance by cancer 
cells. The mechanism of action of cisplatin involves its 
interaction with DNA to form DNA adducts, primarily 
intrastrand crosslink adducts (Gómez-Ruiz et al., 2012; 
Florea, Büsselberg, 2011).
Extensive research efforts have been directed 
towards the development of novel platinum compounds 
with a broader spectrum of antitumor activity, reduced 
side effects and having improved pharmacokinetic 
properties. Besides, the design of new platinum-based 
anti-cancer agents might help to overcome cisplatin 
resistance. The search for new platinum complex is an 
ever present issue because of the potential of this class 
of compounds as antitumor agents (Hildebrandt et al., 
2016; Lakomska et al., 2016; Pollak, Goddard, Porschke, 
2016; Popova et al., 2016; Rehm et al., 2016; Wang et 
al., 2016). 
Many platinum complexes have been shown to 
inhibit the growth of cancer cells. These compounds 
have, in general, at least one amino group, which is 
important for hydrogen-bonding to DNA (Ahmad, Isab, 
Ali, 2006). Furthermore, the variation of the ligands on 
the metal centre is a valuable strategy for modeling the 
physicochemical properties, increasing the uptake of 
platinum compounds (Graf, Lippard, 2012).
Based on the potential of platinum complexes as 
anticancer agents and in order to obtain new, more potent 
and less toxic cisplatin analogues, we set out to synthesize 
novel cis-diammine platinum complexes, derived from 
epichlohydrin or pentaerythritol (Figure 1). 
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The compounds were screened for their ability 
to inhibit the proliferation of four human cell lines 
representing breast (MCF-7), colorectal (HCT116), 
leukaemia (HL-60) and T lymphocytic (Jurkat) cancers. 
The effects of the different ligands on the cytotoxic activity 
of platinum complexes have been investigated. Among the 
synthesized compounds, one was selected for evaluation 
on mice bearing solid Ehrlich tumor.
MATERIALAND METHODS
General procedures
Melting points were determined on a Microquimica 
MQAPF 301 apparatus and are uncorrected FT-IR 
spectra were recorded using a Perkin Elmer Spectrum 
One infrared spectrometer and absorptions are reported 
as wave numbers (cm-1). NMR spectra were recorded 
on a Bruker Avance DPX 200 SPECTROMETER (200 
MHz). Chemical shifts are given in δ (ppm) scale and 
J values are given in Hz. All reagents of analytical 
grade were obtained from commercial suppliers and 
used without previous purification. Reactions were 
monitored by TLC using silica gel coated plates and 
different solvent solutions as the mobile phase. The 
diazide derivatives 7 (Lopes et al., 2015) and 8 (Bitha et 
al., 1989) were synthesized according to the published 
procedure. 
General procedure for the preparation of the diazide 
derivatives 9-14
A 50% w/v aqueous solution of sodium hydroxide 
was placed into a 50 mL round bottom flask. Then, a 
solution of the appropriate diazide (1equivalent) in ethyl 
ether (double volume regarding the aqueous solution of 
sodium hydroxide) and n-tetrabutylammonium bromide 
(0.3 equivalent) were added to the flask. Finally, the 
alkyl halide (5 equivalent for the preparation of 9-12 and 
10 equivalent for 13-14) was added drop-wise and the 
reaction mixture was stirred at room temperature until 
complete consumption of the starting material, as judged 
by TLC analysis. The reaction mixture was transferred to a 
separatory funnel and the organic layer was collected. The 
aqueous layer was extracted with ethyl ether (4 x 50 mL). 
The ethereal phases were combined, washed with water to 
pH 5, dried (anhydrous Na2SO4), filtered and concentrated 
to dryness. The crude compound was purified by column 
chromatography.
1,3-Diazido-2-ethoxypropane (9)
Oil, 52% yield. IR (ῡ/cm-1): 2979, 2931 and 2877 
(sp3 CH stretching), 2089 (N3 stretching), 1109 (C-O 
stretching). 1HNMR (200 MHz, CDCl3), δ/ppm: 3.71-
3.54 (3H, m, CHO and CH2O); 3.33 (4H, d, 3J= 7 Hz, 2x 
CH2N3); 1.25 (3H, t, 3J= 7 Hz, CH3). 13CNMR (50 MHz, 
CDCl3), δ/ppm: 77.6 (CHO); 66.0 (CH2O); 51.6 (CH2N); 
15.3 (CH3).
1,3-Diazido-2-n-butyloxypropane (10)
Oil, 50% yield. IR (ῡ/cm-1): 2960, 2934 and 2872 
(sp3 CH stretching), 2091 (N3 stretching), 1111 (C-O 
stretching). 1HNMR (200 MHz, CDCl3), δ/ppm: 3.62-
3.51 (3H, m, CHO and CH2O); 3.34 (4H, d, 3J= 5 Hz, 2x 
CH2N3); 1.67-1.49 (2H, m, CH2); 1.46-1.31 (2H, m, CH2); 
0.93 (3H, t, 3J= 7 Hz, CH3). 13CNMR (50 MHz, CDCl3), δ/
ppm: 77.8 (CHO); 70.5 (CH2O); 52.0 (CH2N); 31.9 (CH2); 
19.1 (CH2); 13.8 (CH3).
1,3-Diazido-2-octyloxypropane (11)
Oil, 63% yield. IR (ῡ/cm-1): 2926 and 2856 (sp3 CH 
stretching), 2093 (N3 stretching), 1111 (C-O stretching); 
723 (CH2 rocking). 1HNMR (200 MHz, CDCl3), δ/ppm: 
3.61-3.51 (3H, m, CHO and CH2O); 3.34 (4H, d, 3J= 7 
Hz, 2x CH2N3); 1.65-1.56 (2H, m, CH2); 1.45-1.15 (10H, 
m, CH2); 0.88 (3H, t, 3J= 6 Hz, CH3). 13CNMR (50 MHz, 
CDCl3), δ/ppm: 77.8 (CHO); 70.6 (CH2O); 51.7 (CH2N); 
31.7 (CH2); 29.8 (CH2); 29.3 (CH2); 29.1 (CH2); 25.9 
(CH2); 22.5 (CH2); 15.3 (CH3).
1,3-Diazido-2-benzyloxypropane (12)
Oil, 45% yield. IR (ῡ/cm -1): 3032 (arom CH 
stretching), 2930 and 2869 (sp3 CH stretching), 2090 (N3 
stretching), 1496 and 1494 (arom C=C stretching), 1095 
(C-O stretching), 737, 696 (CH bending, phenyl). 1HNMR 
(200 MHz, CDCl3), δ/ppm: 7.43 (5H, broad singlet, 
C6H5); 4.70 (2H, s, CH2O); 3.71 (1H, q, 3J= 5.8, CHO); 
3.39 (4H, d, 3J= 5.8 Hz, 2x CH2N3). 13CNMR (50 MHz, 
CDCl3), δ/ppm: 137.2 (C ipso); 128.5 (C para); 128.1 
(C meta); 127.9 (C ortho), 76.9 (CHO); 72.4 (CH2O); 
51.6 (CH2N).
FIGURE 1 - Structure of the platinum complexes synthesized.
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2,2-Bis(2-azidomethyl)-1,3-bis(ethoxy)propane (13)
Oil, 43 % yield. IR (ῡ/cm-1): 2977, 2934, 2871 and 
2804 (sp3 CH stretching), 2093 (N3 stretching), 1105 (C-O 
stretching). 1HNMR (200 MHz, CDCl3), δ/ppm: 3.46 (4H, 
q, 3J= 7Hz, CH2O); 3.33 (4H, s, 2x CH2O); 3.30 (4H, s, 
2 x CH2N); 1.17 (6H, t, 3J= 7 Hz, 2 x CH3). 13CNMR (50 
MHz, CDCl3), δ/ppm: 68.9 (CH2O); 66.7 (CH2O); 51.8 
(CH2N); 45.1 (quaternary C); 14.9 (CH3).
2,2-Bis(2-azidomethyl)-1,3-bis(butyloxy)propane (14)
Oil, 35 % yield. IR (ῡ/cm-1): 2959, 2934, 2867 and 
2801 (sp3 CH stretching), 2094 (N3 stretching), 1100 
(C-O stretching). 1HNMR (200 MHz, CDCl3), δ/ppm: 
3.43-3.29 (12H, m, 4 x CH2O, 2 x CH2N); 1.58-1.29 (8H, 
4 x CH2); 0.91 (6H, t, 3J= 7Hz, 2 x CH3) 13CNMR (50 
MHz, CDCl3), δ/ppm: 71.2 (CH2O); 69.2 (CH2O); 51.8 
(CH2N); 45.1 (quaternary C); 31.4 (CH2); 19.4 (CH2); 
13.8 (CH3).
General procedures for the preparation of diamines 
15-17 and 19-20: catalytic hydrogenation
A solution of the he appropriately alkylated diazide 
(1 equivalent) in methanol was placed into a 50 mL round 
bottom flask. Palladium 10% on carbon (40% of the 
weight of the diazide) was added and the heterogeneous 
mixture was stirred at room temperature under a hydrogen 
atmosphere until complete consumption of the starting 
material, as judged by TLC analysis. The catalyst was 
removed by filtration and the solvent distilled off using a 
rotary evaporator. The crude compound was used in the 
next step without further purification.
Procedure for the preparation of diamine 18: 
Staudinger reduction with triphenylphosphine
A solution of diazide 12 (1 eq) and triphenylphosphine 
(2 eq) in tetrahydrofuran (5 mL) was added to a 25 mL 
round bottom flask. The reaction mixture was set aside 
until the complete consumption of the starting material, as 
judged by TLC analysis. The solvent was removed with a 
stream of nitrogen and the residue dissolved in HCl 1 mol 
L-1. This solution was transferred to a separatory funnel 
and extracted with ethyl acetate (5 x 30 mL) to remove 
impurities. The acidic solution was then evaporated 
to dryness to furnish the diamine 18 in the form of a 
hygroscopic dihydrochloride.
2-Ethoxy-1,3-diaminopropane (15)
Oil, 86 % yield. IR (ῡ/cm-1): 3400, 3290 (NH 
stretching), 2973, 2928, 2872 (sp3 CH stretching), 1571 
(NH bending), 1082 (C-O stretching).
2-Butyloxy-1,3-diaminopropane (16)
Oil, 74 % yield. IR (ῡ/cm-1): 3364, 3294 (NH 
stretching), 2957, 2932, 2868 (sp3 CH stretching), 1587 
(NH bending), 1100 (C-O stretching).
2-Octyloxy-1,3-diaminopropane (17)
Oil, 95 % yield. IR (ῡ/cm-1): 3241, 3190 (NH 
stretching), 2922, 2852 (sp3 CH stretching), 1585 (NH 
bending), 1103 (C-O stretching), 723 (CH2 rocking).
2-Benzyloxy-1,3-diaminopropane (18)
Oil, 80 % yield. IR (ῡ/cm-1): 3400, 3290 (NH 
stretching), 2973, 2928, 2872 (sp3 CH stretching), 1571 
(NH bending), 1082 (C-O stretching), 744, 700 (CH 
bending, phenyl).
2,2-Bis(2-aminoethyl)-1,3-bis(ethoxy)propane (19)
Oil, 86 % yield. IR (ῡ/cm-1): 3373, 3270 (NH 
stretching), 2974, 2932, 2867 (sp3 CH stretching), 1571 
(NH bending), 1102 (C-O stretching).
2,2-Bis(2-aminoethyl)-1,3-bis(butyloxy)propane (20)
Oil, 89 % yield. IR (ῡ/cm-1): 3430, 3292 (NH 
stretching), 2957, 2931, 2863 (sp3 CH stretching), 1579 
(NH bending), 1103 (C-O stretching).
General procedure: synthesis of platinum complexes 
To an aqueous solution of K2PtCl4 was added 
dropwise an equimolar amount of the appropriate diamine 
derivative dissolved in water. The reaction mixture was 
stirred for 90 minutes at room temperature, the complex 
which precipitates was filtrated, washed with distilled 
water an dried.
Complex 1
Solid, m.p. 215 oC (decomposition), 19% yield. IR 
(ῡ/cm-1): 3600-3100, (NH stretching), 2970, 2850 (sp3 CH 
stretching), 1572 (NH bending), 1040 (C-O stretching), 
485, 415 (Pt-N stretching), 347, 303 (Pt-Cl stretching).
Complex 2
Solid, m.p. 199 oC (decomposition), 55% yield. IR 
(ῡ/cm-1): 3600-3100, (NH stretching), 2959, 2872 (sp3 CH 
stretching), 1587 (NH bending), 1106 (C-O stretching), 
531, 429 (Pt-N stretching), 329, 312 (Pt-Cl stretching).
Complex 3
Solid, m.p. 194 oC (decomposition), 50% yield. IR 
(ῡ/cm-1): 3600-3100, (NH stretching), 2928, 2856 (sp3 CH 
stretching), 1578 (NH bending), 1105 (C-O stretching), 
468 (Pt-N stretching), 312 (Pt-Cl stretching).
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Complex 4
Solid, m.p. 281 oC (decomposition), 12% yield. IR 
(ῡ/cm-1): 3600-3100, (NH stretching), 2936, 2856 (sp3 CH 
stretching), 1571 (NH bending), 1091 (C-O stretching), 
740, 698 (CH bending, phenyl), 470 (Pt-N stretching), 
328, 318 (Pt-Cl stretching). 
Complex 5
Solid, m.p. 211 oC (decomposition), 30% yield. 
IR (ῡ/cm-1): 3600-3100, (NH stretching), 2974, 2932, 
2871 (sp3 CH stretching), 1587 (NH bending), 1112 
(C-O stretching), 472 (Pt-N stretching), 324, 312 (Pt-Cl 
stretching). 
Complex 6
Solid, m.p. 257 oC (decomposition), 41% yield. IR 
(ῡ/cm-1): 3600-3100, (NH stretching), 2958, 2872 (sp3 CH 
stretching), 1584 (NH bending), 1120 (C-O stretching), 
457 (Pt-N stretching), 323 (Pt-Cl stretching). 
Cytotoxicity assays. The screening assays were 
performed in 96 well plates pre-incubated for 24 h at 
37 ºC to allow adaptation of cells prior to the addition 
of the compounds at 50 µM. Treated and untreated 
cells (DMSO 0.5%) were incubated for 48 hours and 
compounds that inhibited the cell viability greater than 
50% had the IC50 values obtained graphically from 
concentration-effect curves using Prism 5.0 (GraphPad 
Software Inc.). Cisplatin was used as positive control 
under the same experimental conditions. All substances 
were evaluated in two independent experiments, in 
triplicate. Cell viability was estimated by MTT assay 
(Mosmann, 1983).
In vivo experiments. Female Swiss albino mice 
weighing 25–30 g, 6 weeks old, were obtained from 
Faculdade de Farmácia da Universidade Federal de Minas 
Gerais. The animals were housed in plastic cages with 
free access to food and water. The protocol was approved 
by the Ethics Committee for Animal Experiments at 
the Universidade Federal de Minas Gerais (protocol 
236/2013) and are in compliance with the guide for the 
care and use of laboratory animals recommended by the 
Institute of Laboratory Animal Resources. 
Ehrlich solid tumor 
Ehrlich ascites tumor (EAT) cells from the peritoneal 
cavity of Swiss mice were cultured and solid tumors 
were induced as previously described by us (Lages et 
al., 2013). Briefly, solid tumors were induced in mice by 
subcutaneous inoculation of 0.2 mL containing 3 × 106 
viable tumor cells on the left flank. After the inoculation 
of Ehrlich ascites tumor cells, over 90 per cent of the mice 
developed solid tumors. Tumor growth was determined 
by caliper measurement of the largest diameter and its 
perpendicular. Tumor size was calculated as: tumor size 
(mm3) = a x (b)2/2, where a: the largest diameter and; b is 
its perpendicular. 
When the primary tumor reached a size of 
approximately 290 mm3 (day 0), animals were divided into 
three groups, each composed of 6 mice. Groups 1: control 
group treated only with a mixture of dimethylacetamide 
(DMA): PEG-300:Tween 80:saline (6:9:5:80 v/v); Group 
2: group treated with complex 3 (4 mg/kg), twice a week 
for a period of 2 weeks; and Group 3: group treated with 
cisplatin (4 mg/kg). The compounds was dissolved in a 
mixture of DMA:PEG-300:Tween 80:saline (6:9:5:80) 
so that the volume to be administered to each animal was 
0.1 ml. The mice were treated by intratumoral injection. At 
the end of the experiments, the animals were euthanized 
by cervical dislocation under anesthesia with a ketamine-
xylazine mixture. 
Statistical analysis
All data are presented as mean ± sd. Data were 
analyzed using the Minitab software (version 14.0). 
Statistical significance of differences between data was 
evaluated by General Linear Model ANOVA using the t 
student test. A value of p<0.05 was considered significant.
RESULTS AND DISCUSSION
The platinum complexes 1-6 were synthesized 
using the corresponding diazide derivatives 7 and 8 as 
key intermediates. The azido-alcohols 7 and 8 were used 
in the synthesis of the azido-ethers 9-14 by phase-transfer 
catalyzed alkylations, which, except for 12, were reduced 
under hydrogenation conditions in presence of Pd/C to 
afford the corresponding diamine derivative 15-20 in 74-
95% yield. Chemoselective reduction of compound 12 was 
achieved following the method described by Staudinger, 
Meyer (1919), using triphenylphosphine. The platinum 
complexes 1-6 were synthesized by reaction of equimolar 
amount of the appropriate diamine with K2PtCl4, in 12-55% 
(Scheme 1).
The platinum complexes 1-6 were assayed in vitro 
at 50 μM against four human cancer cells lines MCF-7 
(breast), HCT116 (colorectal), HL-60 (leukaemia) and 
Jurkat (T lymphocytic), using cisplatin as standard control 
drug. The concentrations that cause 50% inhibition of 
the tumor cell growth (GI50) were evaluated for the 
more potent compounds (those presenting more than 
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50% inhibition in the initial screening). The results are 
summarized in Table I.
Based on the results shown in Table I, platinum 
complex 1 was inactive against all of the tested tumor cell 
lines. All other complexes were able to inhibit more than 
50% of the growth of at least one of the cancer cell lines and 
then their GI50 values were determined (IC50 = 4-51 µM). 
The human acute myeloid leukemia cell line HL60 was 
more sensitive to the action of the compounds. Complexes 
3 and 6 showed activity comparable to cisplatin (CI50 = 
2.1 µM) against HL-60 cells, with CI50 values in the low-
micromolar range (6 and 4 µM, respectively). Complexes 
3 and 6 can be considered the most promising compounds 
since they were active against all the assayed tumor cell 
lines, with emphasis on their cytotoxic activity against the 
human breast cancer cell lines MCF-7, which was resistant 
to the action of cisplatin. These results suggest that the 
presence of longer alkyl chain is favorable for the activity, 
perhaps by facilitating the penetration of these complexes 
into the tumor cells. 
Based on the results of in vitro cytotoxicity assay, the 
compound 3 was selected for further in vivo evaluation in 
a mouse model bearing solid Ehrlich tumor. Solid tumor 
was induced in female Swiss albino mice by inoculation 
of Ehrlich ascites tumor cells as previously described by 
us (Lages et al., 2013). Due to its low aqueous solubility, 
SCHEME 1 - Synthetic route for the preparation of platinum complexes 1-6.
TABLE I - Effects of platinum complexes 1-6 on the growth of 




Jurkat HL60 MCF-7 HCT-116
1 >50 >50 >50 >50
2 >50 11.9 >50 >50
3 51.1 6.4 13.7 27.3
4 >50 9.5 >50 >50
5 >50 15.6 >50 >50
6 23.3 4.0 20.7 22.0
cisplatin 11. 7 2.1 >50 12.6
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3 was dispersed in a mixture of dimethylacetamide 
(DMA), polyethylene glycol (PEG-300), Tween 80 and 
saline (6:9:5:80 v/v) and administered by intratumoral 
injection at a dose of 4 mg/Kg. A group of animals treated 
with vehicle alone (n = 6) and a group of animals treated 
with cisplatin at a dose of 4 mg/Kg (n = 6) were included 
as negative and positive controls, respectively. The mice 
were treated twice per week for 2 weeks. 
In the first week of treatment, a marked delay in the 
rate of tumor growth, compared with that of the control 
group (p < 0.05), was observed in the groups treated with 
complex 3 and cisplatin. However, tumor growth increased 
significantly after the eighth day of treatment with 3, 
reaching a size similar to the control group (p > 0.05) (Figure 
2). In contrast, the tumor volume of cisplatin-treated group 
continued to decrease with time and two animals showed 
complete regression of the tumor. It is noteworthy that only 
mice treated with cisplatin exhibited signs of toxicity, such 
as decreased activity, piloerection and weight loss, and two 
animals died before the end of the experiments. 
The variation in the activity of complex 3 may 
be due to the practical difficulty of administration of a 
homogeneous dose, because of its relatively low solubility 
in vehicle. Lipophilic drugs can penetrate into cells more 
easily, but, on the other hand, they can be too insoluble 
in aqueous solution, preventing their use in vivo. The 
administration of lower dose, use of other vehicles or 
formulation options to deliver low-solubility compounds 
are alternatives that can be used in further studies. It is 
worth noting that de molecular mass of 3 (MM= 468.33) 
is 1.56 higher than that of cisplatin (MM= 300.01), so less 
amount of the compound in a molar basis was used. This, 
together with its low solubility indicates, in our view, that 
the compound deserves further investigation.
CONCLUSION
In conclusion, six platinum (II) complexes have been 
synthesized and tested as potential antiproliferative agents 
against four cancer cell lines: breast (MCF-7), colorectal 
(HCT116), leukaemia (HL-60) and T lymphocytic 
(Jurkat). Five of them were found to be effective against 
at least one tumor cell line, at micromolar concentrations. 
Based on the results of in vitro cytotoxicity assay, the 
platinum complex 3, having an alkyl chain of 8 carbon 
atoms, was selected for evaluation on mice bearing solid 
Ehrlich tumor. This compound showed antitumor activity 
only in the first half of the treatment. Further studies aimed 
at enhancing the solubility of compound 3 in the assay 
conditions are needed to confirm its antitumor potential.
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